scholarly journals Lymph Node Tumor Burden Correlates With Tumor Budding and Poorly Differentiated Clusters: A New Prognostic Factor in Colorectal Carcinoma?

2021 ◽  
Vol 12 (3) ◽  
pp. e00303
Author(s):  
Ivan Archilla ◽  
Sherley Díaz-Mercedes ◽  
José Javier Aguirre ◽  
Jordi Tarragona ◽  
Isidro Machado ◽  
...  
2021 ◽  
Vol 20 (4) ◽  
pp. 22-33
Author(s):  
O. A. Maynovskaya ◽  
E. G. Rybakov ◽  
S. V. Chernyshov ◽  
Yu. A. Shelygin ◽  
S. I. Achkasov

AIM to assess prognostic significance of pathologic features of T1 rectal carcinoma in relation to regional lymph nodes involvement (N+).MATERIAL AND METHODS: surgical specimens (n = 66) from rectal resection for carcinoma pT1 were investigated. Following prognosticators were evaluated: depth of submucosal invasion, grade of differentiation, lymphovascular invasion (LVI), tumor budding (Bd), poorly differentiated clusters (PDC) of tumor and rupture of cancer glands (CGR).RESULTS: lymph nodes metastases were found in 13 (19.7%) specimens. LVI was associated lymphatic spread in great possibility OR 38.0 95% CI 2.1-670 (p < 0.0001). Tumor budding of high grade (Bd3) OR 6.2 95% CI 1.2-31 (p < 0.0001) and poorly differentiated clusters (p = 0,03) also increased risk of lymph node metastases. Depth of submucosal invasion, grade of differentiation, and rupture of cancer glands failed to demonstrate significant association with N+. Logistic regression analysis allowed to determine LVI as independent prognostic factor of lymph node tumor involvement.CONCLUSION: lymphovascular invasion, tumor budding and poorly differentiated clusters of tumor are risk factors of T1 rectal carcinoma lymph node metastases.


2014 ◽  
Vol 146 (5) ◽  
pp. S-335
Author(s):  
Hector H. Li-Chang ◽  
Bojana Mitrovic ◽  
Kelly Handley ◽  
Richard Gray ◽  
Naziheh Assarzadegan ◽  
...  

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 2982 ◽  
Author(s):  
Paolo Giuffrida ◽  
Giovanni Arpa ◽  
Alessandro Vanoli ◽  
Antonio Di Sabatino

We read with interest the paper by Jun S [...]


2017 ◽  
Vol 471 (6) ◽  
pp. 731-741 ◽  
Author(s):  
Luca Reggiani Bonetti ◽  
Simona Lionti ◽  
Enrica Vitarelli ◽  
Valeria Barresi

2021 ◽  
Vol 9 (A) ◽  
pp. 789-797
Author(s):  
Amira Mohamed Bassam ◽  
Yousra Raafat ◽  
Ahmed Mahmoud Abd Al-Aziz ◽  
Rasha Ramadan Mostafa

BACKGROUND: Tumor budding is associated with adverse histology and is a predictor of lymph node metastasis. Human chorionic gonadotropin-beta (hCG-β) expression in non-trophoblastic tumors has been associated with aggressive behavior. AIM: Evaluation of tumor budding and hCG-β _immunohistochemical expression in colorectal carcinoma (CRC), and correlation of their expression with various clinicopathological parameters. MATERIALS AND METHODS: Immunohistochemical staining for hCG-β _was performed on paraffin-embedded sections of 60 cases of CRC. Tumors with cytoplasmic or membranous staining of more than five epithelial cell clusters were designated hCG-β _positive; otherwise, they were designated hCG-β _negative. Tumor budding was assessed in hematoxylin and eosin stained slides and was classified as; low: 0–4 buds, intermediate: 5–9 buds and high: ≥10 buds; with exclusion of pure mucoid or signet ring cell morphology cases from analysis. RESULTS: Tumor budding was low in (58.8%) of the cases, intermediate in (15.7%), and high in (25.5%). There was a statistically significant correlation between tumor budding and tumor histological grade (p = 0.011), lymph node metastasis (N) (p = 0.009), overall pathologic stage group (p = 0.009), modified Dukes’ stage (p = 0.009), lymphovascular invasion (p = 0.000), and desmoplastic reaction (p = 0.004). Positive hCG-β _alpha expression was detected in 12 (20%) of cases. There were statistically significant correlations between hCG-β _expression and each of lymphovascular invasion (p = 0.042) and tumor budding (p = 0.000). CONCLUSION: hCG-β _is a marker of aggressiveness that may have essential role in tumor invasion. Tumor budding is crucial event in tumor invasion and metastasis. Tumor budding with hCG-β _expression is a novel prognostic parameter and may represent a potential therapeutic target.


2018 ◽  
Vol 142 (8) ◽  
pp. 952-957 ◽  
Author(s):  
Soo-Jin Cho ◽  
Sanjay Kakar

Context.— Tumor budding has received increasing recognition as an important independent prognostic factor in colorectal carcinoma. Prominent tumor budding in adenocarcinoma arising in a polyp has been shown to be a risk factor for lymph node involvement. The variability in methods used for evaluating tumor budding in different studies and lack of standardized guidelines have impeded routine inclusion of tumor budding in pathology reports. This changed last year with consensus guidelines based on the International Tumor Budding Consensus Conference (ITBCC). These guidelines have been included in the recent College of American Pathologists (CAPs) Colorectal Cancer Protocol. The consensus methodology will allow uniform reporting of this finding, but challenges in interpretation in the setting of intense inflammation, fibrosis, or gland fragmentation need to be addressed in future guidelines. Objective.— To provide a brief overview of the known clinical significance of tumor budding in colorectal carcinoma and discuss the practical aspects of its implementation on a routine basis. Data Sources.— English-language pathology literature. Conclusions.— Tumor budding has been shown to be an independent prognostic marker in colorectal carcinomas and the routine reporting of tumor buds is now advocated by using the approach outlined by the ITBCC guidelines. Tumor budding is included in the CAP protocol as a recommended element. Presence of prominent tumor budding in an adenocarcinoma in a polyp may have implications for management, such as additional resection, while it serves as a prognostic factor in other settings.


Sign in / Sign up

Export Citation Format

Share Document